Erratum: Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages (Cell Reports (2018) 23(4) (1099–1111), (S2211124718304856), (10.1016/j.celrep.2018.03.109));Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages

Cell Reports

Volumn 23, Issue 4, 2018, Pages 1099-1111

  Krishnan, Smitha ^a   Ding, Yufang ^b   Saedi, Nima ^c   Choi, Maria ^a   Sridharan, Gautham V ^a   Sherr, David H ^d   Yarmush, Martin L ^c   Alaniz, Robert C ^e   Jayaraman, Arul ^b,e,f   Lee, Kyongbum ^a  

^a Tufts University   (United States)

^b Texas A M University   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e TEXAS A M COLLEGE OF MEDICINE   (United States)

^f Department of Electrical and Computer Engineering   (United States)

Author keywords

aryl hydrocarbon receptor; gut microbiota; indole 3 acetate; inflammation; metabolomics; nonalcoholic fatty liver disease

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYTOKINE; DRUG METABOLITE; FATTY ACID; FATTY ACID SYNTHASE; INDOLEACETIC ACID; LIPID; LIPOPOLYSACCHARIDE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRYPTOPHAN; INDOLEACETIC ACID DERIVATIVE; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRYPTAMINE; TRYPTAMINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; INFANT; INFLAMMATION; INTESTINE FLORA; LIPID DIET; LIVER CELL; LOW FAT DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; FAT INTAKE; HEP-G2 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHARMACOLOGY; RAW 264.7 CELL LINE;

ANIMALS; CYTOKINES; DIETARY FATS; FATTY ACID SYNTHASE, TYPE I; GASTROINTESTINAL MICROBIOME; HEP G2 CELLS; HEPATOCYTES; HUMANS; INDOLEACETIC ACIDS; INFLAMMATION; MACROPHAGES; MALE; MICE; RAW 264.7 CELLS; RECEPTORS, ARYL HYDROCARBON; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRYPTAMINES; TRYPTOPHAN;

EID: 85045954399     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2019.08.080     Document Type: Erratum

References (54)

1. Allen, F., Pon, A., Wilson, M., Greiner, R., Wishart, D., CFM-ID: a web server for annotation, spectrum prediction and metabolite identification from tandem mass spectra. Nucleic Acids Res. 42 (2014), W94–W99.
2. Aranha, M.M., Cortez-Pinto, H., Costa, A., da Silva, I.B., Camilo, M.E., de Moura, M.C., Rodrigues, C.M., Bile acid levels are increased in the liver of patients with steatohepatitis. Eur. J. Gastroenterol. Hepatol. 20 (2008), 519–525.
3. Asgharpour, A., Cazanave, S.C., Pacana, T., Seneshaw, M., Vincent, R., Banini, B.A., Kumar, D.P., Daita, K., Min, H.K., Mirshahi, F., et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J. Hepatol. 65 (2016), 579–588.
4. Baeck, C., Wehr, A., Karlmark, K.R., Heymann, F., Vucur, M., Gassler, N., Huss, S., Klussmann, S., Eulberg, D., Luedde, T., et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61 (2012), 416–426.
5. Bansal, T., Alaniz, R.C., Wood, T.K., Jayaraman, A., The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc. Natl. Acad. Sci. USA 107 (2010), 228–233.
6. Buzzetti, E., Pinzani, M., Tsochatzis, E.A., The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65 (2016), 1038–1048.
7. Chow, M.D., Lee, Y.H., Guo, G.L., The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol. Aspects Med. 56 (2017), 34–44.
8. Day, C.P., Non-alcoholic fatty liver disease: a massive problem. Clin. Med. (Lond.) 11 (2011), 176–178.
9. Dowman, J.K., Tomlinson, J.W., Newsome, P.N., Pathogenesis of non-alcoholic fatty liver disease. QJM 103 (2010), 71–83.
10. Drozdzik, A., Dziedziejko, V., Kurzawski, M., IL-1 and TNF-α regulation of aryl hydrocarbon receptor (AhR) expression in HSY human salivary cells. Arch. Oral Biol. 59 (2014), 434–439.
11. Endo, M., Masaki, T., Seike, M., Yoshimatsu, H., TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp. Biol. Med. (Maywood) 232 (2007), 614–621.
12. Eslam, M., Valenti, L., Romeo, S., Genetics and epigenetics of NAFLD and NASH: clinical impact. J. Hepatol. 68 (2018), 268–279.
13. García-Ruiz, I., Solís-Muñoz, P., Fernández-Moreira, D., Muñoz-Yagüe, T., Solís-Herruzo, J.A., In vitro treatment of HepG2 cells with saturated fatty acids reproduces mitochondrial dysfunction found in nonalcoholic steatohepatitis. Dis. Model. Mech. 8 (2015), 183–191.
14. Gharavi, N., El-Kadi, A.O., Down-regulation of aryl hydrocarbon receptor-regulated genes by tumor necrosis factor-alpha and lipopolysaccharide in murine hepatoma Hepa 1c1c7 cells. J. Pharm. Sci. 94 (2005), 493–506.
15. Ghazalpour, A., Cespedes, I., Bennett, B.J., Allayee, H., Expanding role of gut microbiota in lipid metabolism. Curr. Opin. Lipidol. 27 (2016), 141–147.
16. Gorski, J.R., Weber, L.W., Rozman, K., Tissue-specific alterations of de novo fatty acid synthesis in 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-treated rats. Arch. Toxicol. 62 (1988), 146–151.
17. Haukeland, J.W., Damås, J.K., Konopski, Z., Løberg, E.M., Haaland, T., Goverud, I., Torjesen, P.A., Birkeland, K., Bjøro, K., Aukrust, P., Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 44 (2006), 1167–1174.
18. Hubbard, T.D., Murray, I.A., Bisson, W.H., Lahoti, T.S., Gowda, K., Amin, S.G., Patterson, A.D., Perdew, G.H., Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. Sci. Rep., 5, 2015, 12689.
19. Jin, U.H., Lee, S.O., Sridharan, G., Lee, K., Davidson, L.A., Jayaraman, A., Chapkin, R.S., Alaniz, R., Safe, S., Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities. Mol. Pharmacol. 85 (2014), 777–788.
20. Kim, K.A., Gu, W., Lee, I.A., Joh, E.H., Kim, D.H., High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS ONE, 7, 2012, e47713.
21. Lakshman, M.R., Campbell, B.S., Chirtel, S.J., Ekarohita, N., Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on de novo fatty acid and cholesterol synthesis in the rat. Lipids 23 (1988), 904–906.
22. Le Roy, T., Llopis, M., Lepage, P., Bruneau, A., Rabot, S., Bevilacqua, C., Martin, P., Philippe, C., Walker, F., Bado, A., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62 (2013), 1787–1794.
23. Lee, J.H., Wada, T., Febbraio, M., He, J., Matsubara, T., Lee, M.J., Gonzalez, F.J., Xie, W., A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology 139 (2010), 653–663.
24. Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 686–690.
25. Malhi, H., Bronk, S.F., Werneburg, N.W., Gores, G.J., Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem. 281 (2006), 12093–12101.
26. Manteiga, S., Lee, K., Monoethylhexyl phthalate elicits an inflammatory response in adipocytes characterized by alterations in lipid and cytokine pathways. Environ. Health Perspect. 125 (2017), 615–622.
27. Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M.L., Perotti, G., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49 (2009), 1877–1887.
28. Murphy, E.A., Velazquez, K.T., Herbert, K.M., Influence of high-fat diet on gut microbiota: a driving force for chronic disease risk. Curr. Opin. Clin. Nutr. Metab. Care 18 (2015), 515–520.
29. Nagy, S.R., Sanborn, J.R., Hammock, B.D., Denison, M.S., Development of a green fluorescent protein-based cell bioassay for the rapid and inexpensive detection and characterization of ah receptor agonists. Toxicol. Sci. 65 (2002), 200–210.
30. Pagadala, M., Kasumov, T., McCullough, A.J., Zein, N.N., Kirwan, J.P., Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol. Metab. 23 (2012), 365–371.
31. Pang, J., Xi, C., Huang, X., Cui, J., Gong, H., Zhang, T., Effects of excess energy intake on glucose and lipid metabolism in C57BL/6 mice. PLoS ONE, 11, 2016, e0146675.
32. Pelclová, D., Fenclová, Z., Preiss, J., Procházka, B., Spácil, J., Dubská, Z., Okrouhlík, B., Lukás, E., Urban, P., Lipid metabolism and neuropsychological follow-up study of workers exposed to 2,3,7,8- tetrachlordibenzo- p-dioxin. Int. Arch. Occup. Environ. Health 75:Suppl (2002), S60–S66.
33. Reid, D.T., Eksteen, B., Murine models provide insight to the development of non-alcoholic fatty liver disease. Nutr. Res. Rev. 28 (2015), 133–142.
34. Ricchi, M., Odoardi, M.R., Carulli, L., Anzivino, C., Ballestri, S., Pinetti, A., Fantoni, L.I., Marra, F., Bertolotti, M., Banni, S., et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J. Gastroenterol. Hepatol. 24 (2009), 830–840.
35. Schilling, J.D., Machkovech, H.M., He, L., Sidhu, R., Fujiwara, H., Weber, K., Ory, D.S., Schaffer, J.E., Palmitate and lipopolysaccharide trigger synergistic ceramide production in primary macrophages. J. Biol. Chem. 288 (2013), 2923–2932.
36. Schippa, S., Conte, M.P., Dysbiotic events in gut microbiota: impact on human health. Nutrients 6 (2014), 5786–5805.
37. Schwartz, E.A., Zhang, W.Y., Karnik, S.K., Borwege, S., Anand, V.R., Laine, P.S., Su, Y., Reaven, P.D., Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler. Thromb. Vasc. Biol. 30 (2010), 802–808.
38. Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., Flier, J.S., TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116 (2006), 3015–3025.
39. Smith, C.A., O'Maille, G., Want, E.J., Qin, C., Trauger, S.A., Brandon, T.R., Custodio, D.E., Abagyan, R., Siuzdak, G., METLIN: a metabolite mass spectral database. Ther. Drug Monit. 27 (2005), 747–751.
40. Sridharan, G.V., Choi, K., Klemashevich, C., Wu, C., Prabakaran, D., Pan, L.B., Steinmeyer, S., Mueller, C., Yousofshahi, M., Alaniz, R.C., et al. Prediction and quantification of bioactive microbiota metabolites in the mouse gut. Nat. Commun., 5, 2014, 5492.
41. Stojsavljević, S., Gomerčić Palčić, M., Virović Jukić, L., Smirčić Duvnjak, L., Duvnjak, M., Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J. Gastroenterol. 20 (2014), 18070–18091.
42. Tacke, F., Zimmermann, H.W., Macrophage heterogeneity in liver injury and fibrosis. J. Hepatol. 60 (2014), 1090–1096.
43. Tanos, R., Murray, I.A., Smith, P.B., Patterson, A., Perdew, G.H., Role of the Ah receptor in homeostatic control of fatty acid synthesis in the liver. Toxicol. Sci. 129 (2012), 372–379.
44. Vernocchi, P., Del Chierico, F., Putignani, L., Gut microbiota profiling: metabolomics based approach to unravel compounds affecting human health. Front. Microbiol., 7, 2016, 1144.
45. Wada, T., Sunaga, H., Miyata, K., Shirasaki, H., Uchiyama, Y., Shimba, S., Aryl hydrocarbon receptor plays protective roles against high fat diet (HFD)-induced hepatic steatosis and the subsequent lipotoxicity via direct transcriptional regulation of Socs3 gene expression. J. Biol. Chem. 291 (2016), 7004–7016.
46. Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M.T., Brickey, W.J., Ting, J.P., Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12 (2011), 408–415.
47. Wikoff, W.R., Anfora, A.T., Liu, J., Schultz, P.G., Lesley, S.A., Peters, E.C., Siuzdak, G., Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA 106 (2009), 3698–3703.
48. Williams, B.B., Van Benschoten, A.H., Cimermancic, P., Donia, M.S., Zimmermann, M., Taketani, M., Ishihara, A., Kashyap, P.C., Fraser, J.S., Fischbach, M.A., Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe 16 (2014), 495–503.
49. Wishart, D.S., Tzur, D., Knox, C., Eisner, R., Guo, A.C., Young, N., Cheng, D., Jewell, K., Arndt, D., Sawhney, S., et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 35 (2007), D521–D526.
50. Wolf, S., Schmidt, S., Müller-Hannemann, M., Neumann, S., In silico fragmentation for computer assisted identification of metabolite mass spectra. BMC Bioinformatics, 11, 2010, 148.
51. Ying, W., Cheruku, P.S., Bazer, F.W., Safe, S.H., Zhou, B.Y., Investigation of macrophage polarization using bone marrow derived macrophages. J. Vis. Exp., 76, 2013, 10.3791/50323.
52. Zhang, J., Zhao, Y., Xu, C., Hong, Y., Lu, H., Wu, J., Chen, Y., Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci. Rep., 4, 2014, 5832.
53. Zhao, B., Degroot, D.E., Hayashi, A., He, G., Denison, M.S., CH223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor. Toxicol. Sci. 117 (2010), 393–403.
54. Zhu, L., Baker, S.S., Gill, C., Liu, W., Alkhouri, R., Baker, R.D., Gill, S.R., Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57 (2013), 601–609.